NEW YORK (GenomeWeb) – Beam Therapeutics announced today that it has launched with $87 million in Series A funding to develop precision genetic medicines that make edits to individual base pairs in the genome.
The funding round was led by F-Prime Capital Partners and ARCH Venture Partners.